

Special Issue

New Discoveries in Drug Targets and Delivery for Alzheimer's Disease

Message from the Guest Editors

Alzheimer's Disease, the most common cause of dementia, affects over 40 million people worldwide. The situation is expected to intensify in the coming years, with devastating social and economic effects. Despite intensive clinical research efforts, there are currently no treatments or effective preventive strategies for AD. In fact, FDA-approved drugs only relieve symptoms. The main reasons for AD treatment's failure are the multifactorial and heterogeneous physiopathological mechanisms of the disease, erroneous selection of drug targets, lack of relevant animal models, and obstacles in drug delivery into the brain due to the high selectivity of the blood–brain barrier, which limits the access of therapeutic agents into the central nervous system. Therefore, this Special Issue aims to collect original research articles and reviews with the most relevant and innovative findings in the field of AD. Manuscripts dealing with new targets and therapeutic strategies, pharmaceutical formulations, and drug delivery systems as well as relevant models used for the development of effective AD treatments are of great interest.

Guest Editors

Dr. Elena Puris

Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Im Neuenheimer Feld 329, D-69120 Heidelberg, Germany

Dr. Sabrina Petralla

Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Im Neuenheimer Feld 329, D-69120 Heidelberg, Germany

Deadline for manuscript submissions

closed (30 October 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/134754

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).